Bibliographic Details
| Title: |
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms. |
| Authors: |
Kopmar, Noam E.1 (AUTHOR), Gooley, Ted2 (AUTHOR), Curley, Niall1 (AUTHOR), Russell, Kathryn1 (AUTHOR), Shaw, Carole3 (AUTHOR), Schonhoff, Kelda1 (AUTHOR), Lim, John1 (AUTHOR), Halpern, Anna B.1,3 (AUTHOR), Walter, Roland B.1,3,4,5 (AUTHOR), Scott, Bart L.1,3 (AUTHOR), Appelbaum, Jacob1 (AUTHOR), Hendrie, Paul C.1 (AUTHOR), Estey, Elihu H.1,3 (AUTHOR), Percival, Mary-Elizabeth M.1,3 (AUTHOR) |
| Source: |
Leukemia & Lymphoma. May2023, Vol. 64 Issue 5, p1057-1059. 3p. |
| Subject Terms: |
*CYTARABINE, *MITOXANTRONE, *GRANULOCYTE-colony stimulating factor, *TUMORS, *BLAST injuries |
| Abstract: |
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. SWOG S1203: a randomized phase III study of standard cytarabine plus daunorubicin (7 + 3) therapy versus idarubicin with high dose cytarabine (IA) with or without vorinostat (IA + V) in younger patients with previously untreated acute myeloid leukemia (AML). Outcomes for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and other high-grade myeloid neoplasms remain poor, prompting the need for improved salvage therapies. [Extracted from the article] |
|
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
